This Executive Order amends a prior order dated February 1, 2025, that imposed duties on products related to synthetic opioid supply chains originating from China. The amendment specifically addresses the treatment of duty-free de minimis imports under U.S. customs regulations (19 U.S.C. 1321), modifying how these small-value shipments will be processed when they contain items covered under the original synthetic opioid supply chain order. The change represents part of the administration's broader strategy to combat illicit drug trafficking and hold foreign entities accountable for their role in the opioid crisis affecting the United States.
The amendment replaces subsection (g) of section 2 in the original Executive Order to create a conditional framework for de minimis treatment of covered articles. Under the new provision, covered articles that would otherwise be eligible for duty-free treatment under the de minimis provision will continue to receive such treatment initially. However, this treatment will cease once the Secretary of Commerce notifies the President that adequate systems have been established to fully and expediently process and collect tariff revenue for these covered articles. This mechanism effectively creates a transitional period for implementation while systems are being developed to ensure tariff collection on these specific imports.
Implementation of this order falls primarily to the Department of Commerce, which is tasked with developing and certifying the adequacy of systems to process tariffs on the covered articles. The order includes standard provisions clarifying that it does not impair existing legal authorities of executive departments or agencies, must be implemented consistent with applicable law, and is subject to the availability of appropriations. Additionally, the order explicitly states it does not create any enforceable rights or benefits for any party against the United States government or its representatives. This amendment appears designed to balance immediate policy objectives regarding Chinese synthetic opioid supply chains with practical considerations about customs enforcement capabilities.